New injection tested to boost heart power in lung pressure disease
NCT ID NCT07177703
Summary
This study is testing if adding an injectable medication called Treprostinil to a patient's existing oral therapy can improve heart function in people with intermediate-risk pulmonary arterial hypertension (PAH). All 32 participants will receive the injection for 3 months while researchers measure changes in how much blood their heart pumps. The goal is to see if this combination approach helps control the disease better than oral medications alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.